Lead Optimization and Pre-Clinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (SBIR (R43/R44))
The summary for the Lead Optimization and Pre-Clinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (SBIR (R43/R44)) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Lead Optimization and Pre-Clinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (SBIR (R43/R44)): The goal of this Funding Opportunity Announcement (FOA) is to support lead optimization and preclinical development of new therapies for diseases within the mission of the NIDDK. Phase I supports preliminary steps in the process for lead optimization or preclinical development of therapeutics. Phase II supports lead optimization and preclinical development of lead candidates and projects must be sufficiently advanced such that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of a Phase II or IIB project. Applications are expected to have defined Milestones and Timelines detailing how the project will move forward with identified key Go / No Go decision points.
Federal Grant Title: | Lead Optimization and Pre-Clinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (SBIR (R43/R44)) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Food and Nutrition Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PA-14-055 |
Type of Funding: | Grant |
CFDA Numbers: | 93.847 |
CFDA Descriptions: | Diabetes, Digestive, and Kidney Diseases Extramural Research |
Current Application Deadline: | Jan 7, 2017 |
Original Application Deadline: | Jan 7, 2017 |
Posted Date: | Jan 2, 2014 |
Creation Date: | Jan 2, 2014 |
Archive Date: | Feb 7, 2017 |
Total Program Funding: | |
Maximum Federal Grant Award: | none |
Minimum Federal Grant Award: | none |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following:
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/pa-files/PA-14-055.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
National Institutes of Health 301-496-3405 - Similar Government Grants
- • Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogen...
- • Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
- • Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors...
- • NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Requ...
- • NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements...
- • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes
- • Molecular Therapy Core Centers
- • Pilot and Feasibility Program in Human Islet Biology
- More Grants from the National Institutes of Health
- • Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical ...
- • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...
- • Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
- • NINDS Program Project Grant (P01 Clinical Trial Optional)
- • Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial N...